Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

26.63 4.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.46

Max

27.3

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+27.69% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

826M

2.9B

Eelmine avamishind

22.08

Eelmine sulgemishind

26.63

Uudiste sentiment

By Acuity

50%

50%

155 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. aug 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19. aug 2026, 23:56 UTC

News
Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19. aug 2026, 23:52 UTC

News
Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19. aug 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19. aug 2026, 23:51 UTC

News
Social Media

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

19. aug 2026, 23:41 UTC

News

Target Corp shares are lower in after-market hours despite stronger-than-expected second-quarter earnings of $4.11 per share and a raised full-year forecast.

19. aug 2026, 23:36 UTC

News
Social Media

Rosenblatt analyst Scott Devitt initiated coverage on Amazon.com with a Buy rating. Shares advanced in after-market trading following this positive assessment.

19. aug 2026, 23:31 UTC

News

Wendy's Co shares are lower in after-market hours following a management reset and reports of Trian Fund Management exploring a potential buyout.

19. aug 2026, 23:26 UTC

News

Constellation Brands announced a $100 million investment over five years to support farmers in Idaho, Montana, and North Dakota. Shares were roughly flat in after-market trading.

19. aug 2026, 23:22 UTC

News
Social Media
Correlated Moves

Coinbase Global Inc shares are higher in after-market trading amid bullish social media sentiment and the announcement of direct USDC trading in Brazil.

19. aug 2026, 23:21 UTC

Social Media
Correlated Moves
News

Marvell Technology shares rise in after-hours trading following a significant deal with Google, which includes a warrant for 58.97 million shares at $206.58 each.

19. aug 2026, 23:21 UTC

Correlated Moves
News

Microstrategy Inc. shares rose in after-market trading, driven by increased bullish options activity and positive remarks on its Bitcoin strategy from executives.

19. aug 2026, 23:21 UTC

News

Kratos Defense shares are rising in after-market trading as the U.S. Air Force evaluates alternatives to existing aerial targets, including the BQM-167A.

19. aug 2026, 23:21 UTC

Event
Social Media
News

BILL Holdings reported strong Q4 results, with adjusted net income of $94 million. Shares are higher in after-hours trading following the earnings report.

19. aug 2026, 23:16 UTC

News

Accuray Inc shares fell in after-market hours following a net loss of $1.94 million and revenue of $100.92 million, missing expectations.

19. aug 2026, 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

19. aug 2026, 23:16 UTC

News
Social Media

Netflix Inc. is trading higher in after-market hours amid reports of competitive strategies in the streaming industry, including YouTube's incentives for exclusive content.

19. aug 2026, 23:11 UTC

News

Carlyle Group invests in Castelion's $1 billion funding round, boosting defense sector engagement. Shares are higher in after-market trading following the announcement.

19. aug 2026, 23:11 UTC

News

Northrop Grumman declared a quarterly dividend of $2.47 per share, contributing to shares trading higher in after-market hours.

19. aug 2026, 23:11 UTC

Correlated Moves
News

The Australian Dollar is gaining against the Hong Kong Dollar amid rising global bond yields and inflation concerns linked to geopolitical tensions.

19. aug 2026, 23:06 UTC

News

Replimune Group shares declined in after-market hours following the grant of equity awards to Chief Commercial Officer Michelle DiNapoli, raising potential dilution concerns.

19. aug 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

19. aug 2026, 23:06 UTC

Social Media
News

Hims & Hers Health Inc. shares are lower in after-market trading following a lawsuit from the FTC alleging deceptive practices regarding user privacy and billing.

19. aug 2026, 23:06 UTC

News

Chewy Inc shares are lower in after-market trading as cautious sentiment grows ahead of the September earnings call and a Neutral rating from Rosenblatt.

19. aug 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and Fed concerns contribute to a decline in the iShares 20+ Year Treasury Bond ETF in after-market trading. The iShares TIPS Bond ETF also moves lower.

19. aug 2026, 23:06 UTC

Social Media
News

SPDR Gold Shares trade higher after-market, boosted by social media discussions on its return above the 200-day moving average amid geopolitical tensions and inflation concerns.

19. aug 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and inflation concerns support iShares Silver Trust's gains during after-market hours, maintaining a position above its 20-day moving average.

19. aug 2026, 23:06 UTC

Correlated Moves
News

Northern Oil and Gas announced a $500 million senior notes offering, contributing to a decline in shares during after-market trading. EOG also fell amid sector dynamics.

19. aug 2026, 23:06 UTC

News
Correlated Moves

Twist Bioscience Corp shares are lower in after-market hours following a critical short report from Scorpion Capital questioning the company's AI-driven protein design strategy.

19. aug 2026, 23:02 UTC

News

Encore Capital Group appoints Robert Beck to its board, effective immediately. The move has contributed to shares rising in after-market trading.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

27.69% tõus

12 kuu keskmine prognoos

Keskmine 32.65 USD  27.69%

Kõrge 45 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

155 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat